HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.6%

Neg 0% Neu 90.6% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.